Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th American Society of Hematology annual meeting | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Emmaus Life Sciences, Inc. to present results of phase 3 study of endariTM (L-glutamine oral powder) at 59th American Society of Hematology annual meeting


Emmaus will present results of a Phase 3 study of Endari (L-glutamine oral powder) for sickle cell disease treatment at the 59th Annual Meeting of the American Society of Hematology (ASH) taking place in Atlanta, Georgia December 9-12, 2017.

Details of the oral presentation are as follows:
Publication Number: 685
Title: Phase 3 Study of L-glutamine in Sickle Cell Disease: Analyses of Time to First and Second Crisis and Average Cumulative Recurrent Events
Name: 114. Hemoglobinopathies, Excluding Thalassemia—Clinical II
Date: Monday, December 11, 2017
Time: 2:45 PM – 4:15 PM
Room: Georgia World Congress Center, Building B, Level 3, B308-B309

https://www.onescdvoice.com/wp-content/uploads/2017/12/Emmaus-Life-Sciences.jpg